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Abstract 
Background: Oxidative stress, inflammation and endothelial dysfunction are interrelated factors in the etiology of 
cardiovascular disease, but their linkage to type 2 diabetes is less clear. We examined the association of these bio-
markers with incident type 2 diabetes (T2D).
Methods: Analysis of 2339 participants in the community-based coronary artery risk development in young adults 
(CARDIA) study. Participants (age 40.1 ± 3.6 years, 44 % Black, 58 % women) were free of diabetes, and were followed 
10 years. Cox regression was used to estimate hazard ratios (HRs) for incident T2D adjusting for the other biomark-
ers under study, demographic and lifestyle measures, dietary biomarkers, BMI (kg/m2) and metabolic syndrome 
components.
Results: F2-isoprostanes and oxidized LDL (oxidative stress) were positively associated with incident T2D, but the 
associations were attenuated by adjustment for BMI. C-reactive protein was positively associated with T2D even 
with full adjustment: HR (95 % CI) = 2.21 (1.26–3.88) for quartile 4 (Q4) v. quartile 1 (Q1). The HR (95 % CI) for T2D for 
biomarkers of endothelial dysfunction ICAM-1 and E-selectin for Q4 v. Q1 were 1.64 (0.96–2.81) and 1.68 (1.04–2.71) 
respectively, with full adjustment. Including these two markers in a common risk score incorporating BMI and clinical 
measures improved the prediction probability of T2D: relative risk for the average person classified up compared to 
the average person classified down: 1.09, (1.06–1.13), P < 0.0001.
Conclusions: Biomarkers of inflammation and endothelial dysfunction were positively associated with incident T2D. 
ICAM-1 and E-selectin add to the prediction of T2D beyond a common risk score.
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Background
Oxidative stress, inflammation, and endothelial dys-
function are interrelated components of an etiologi-
cal network that has been linked to the development of 
cardiovascular disease (CVD) [1]. This relationship with 
CVD is exacerbated in those with perturbations in glu-
cose homeostasis such as insulin resistance and diabetes 
[2, 3]. Oxidative stress, inflammation, and endothelial 
dysfunction may be ameliorated by a healthy diet and 
lifestyle and have also been linked to the etiology of 
insulin resistance and type 2 diabetes (T2D), and thus 
hypothesized as unifying components tying vascular fac-
tors to metabolic and cardiovascular risk [4, 5].
The oxidative stress aspect of this hypothesis is largely 
born out of evidence from animal and in  vitro studies 
demonstrating that chronic levels of oxidative stress are 
among the earliest abnormalities in the natural history 
of insulin resistance and T2D [6]. However, the evidence 
is less developed in human and population based studies 
[7–10]. On the other hand the evidence for inflammation 
in the etiology of T2D is broad. A recent meta-analysis 
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showed a dose–response association between higher lev-
els of inflammatory markers and incidence of T2D [11], 
although the true mechanism is not well understood and 
related evidence suggests that elevated levels of inflam-
mation may be intermediates in the pathophysiology of 
T2D [12]. Related to these concepts, we have previously 
reported that markers of oxidative stress and inflamma-
tion predict the development of insulin resistance and 
the metabolic syndrome [7, 8, 13]. Lastly, endothelial 
dysfunction may be a cause or a consequence of oxida-
tive stress and inflammation and is hypothesized to be 
essential to both the development of T2D and CVD [4]. 
Indeed, a handful of studies have reported that elevated 
markers of endothelial dysfunction are associated with 
increased risk of T2D [14–18].
We are able to study this etiological network of bio-
markers in relation to the incidence of T2D in a different 
context than previous reports. Therefore, we examined 
the associations of oxidative stress (F2-isoprostanes and 
oxidized LDL), inflammation (C-reactive protein), and 
endothelial dysfunction (cellular adhesion molecules) 
with incidence of T2D. We hypothesized that these bio-
markers would positively associate with T2D and add to 




CARDIA is a multicenter, longitudinal investigation of 
the evolution of cardiovascular disease risk starting in 
young adulthood [19]. The study began in 1985–1986 
with 5115 black and white adults aged 18–30 years from 
four metropolitan areas (Birmingham, AL; Chicago, IL; 
Minneapolis, MN; and Oakland, CA). Study participants 
were sampled to obtain roughly equal numbers of blacks 
(51.5  %) and whites (48.5  %), men (45.5  %) and women 
(54.5  %), ages 18–24  years (44.9  %) and 25–30  years 
(55.1 %), and with a high school education or less (39.7 %) 
vs more than a high school education (60.3  %). Partici-
pants were contacted by telephone every year and exam-
ined in person at baseline and 2, 5, 7, 10, 15, 20, and 
25 years after baseline. The CARDIA study was approved 
by the institutional review board of each participating 
institution, is in compliance with the Declaration of Hel-
sinki, and signed informed consent was obtained from 
each participant at each examination.
At each clinical examination, participants were asked 
to present fasting in the morning. Tobacco use, strenuous 
physical activity, and intake of caffeine, food, and alcohol 
were proscribed. The examinations followed standardized 
protocols harmonized over time and included measure-
ments of blood pressure, anthropometrics, phlebotomy, 
and structured questionnaires on socio-demographics, 
medical and family history, psychosocial characteristics, 
and diet, among others.
During each clinic exam blood was drawn from an 
antecubital vein and after serum separation aliquots were 
stored at −70 °C until shipped on dry ice to a central lab-
oratory. Details on the collection and storage of plasma 
samples, laboratory quality-control procedures, and 
methodology for analysis of plasma triglycerides, HDL 
cholesterol, LDL cholesterol, and total cholesterol are 
described elsewhere [20]. Details on the measurement 
and calibration of glucose and insulin [7], blood pressure 
measurement [19], and anthropometry (height, weight, 
waist circumference) have also been previously described 
[21]. Body mass index (BMI) was computed as weight in 
kilograms divided by squared height in meters. Physical 
activity was assessed using an interviewer-administered 
questionnaire which measured the frequency of 13 differ-
ent exercise activities during the past 12 months [22]. The 
total exercise score was in exercise units (a sum across 13 
activities of frequency × intensity).
The measurement of biomarkers of oxidative stress, 
inflammation, endothelial dysfunction and serum carot-
enoids and tocopherols were made as part of the Young 
Adult Longitudinal Trends in Antioxidants (YALTA), 
an ancillary study to CARDIA in the Molecular Epide-
miology and Biomarker Research Laboratory (MEBRL) 
in the University of Minnesota. Specifically, serum oxi-
dized LDL concentrations were measured by competitive 
ELISA (Mercodia, Uppsala, Sweden) [8]. Plasma F2-iso-
prostanes were measured with gas chromatography-mass 
spectrometry [23]. Serum carotenoid and tocopherol 
measurements were based on high performance liquid 
chromatography [24]. High-sensitivity ELISA was used 
to measure serum C-reactive protein (CRP) [13]. Cel-
lular adhesion molecules (CAMs) were measured at the 
MEBRL. E-selectin (serum) and P-selectin (plasma) levels 
were measured with ELISA methods from R and D sys-
tems Inc (Cat No: DSLE00 and BBE6, respectively.) Solu-
ble intercellular adhesion molecule-1 (ICAM-1) (serum) 
and vascular cellular adhesion molecule-1 (VCAM-1) 
(plasma) concentrations were measured by ELISA meth-
ods (R and D systems: DY720 for ICAM-1 and DVC00 
for VCAM [25]. This assay was not affected by ICAM-1 
single nucleotide polymorphism (SNP) rs5491, which 
occurs primarily in blacks and blocks ICAM-1 detection 
by some antibodies.
Assessment of diabetes
Type 2 diabetes was defined as use of diabetes medica-
tion (assessed at every visit), a fasting blood glucose level 
of ≥7 mmol/l (126 mg/dl) (measured at years 15–25), 2 h 
post-challenge glucose  ≥11.1  mmol/l (200  mg/dl) (per-
formed at the year 20, 25 exams), or a HbA1c  ≥6.5  % 
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(48  mmol/mol) (assessed at the year 20 and 25 visits). 
Participants were free of diabetes at year 15 according to 
medication and fasting glucose criteria examined at all 
examinations up to and including year 15.
Statistical analysis
This analysis was restricted to participants in the year 15 
exam, the first exam at which all biomarkers of interest 
were measured in blood collected in a single sitting. We 
included all participants without a history of diabetes or 
an adjudicated cardiovascular disease event prior to year 
15 [26], who also participated in at least one of the year 
20 or 25 exams and had complete data on the spectrum 
of oxidative stress, inflammation, and endothelial dys-
function biomarkers as well as the covariates included 
in the analyses. Final sample size was 2339. Of note, only 
1982 participants had a measure of VCAM. However, 
sensitivity analyses for the other biomarkers limiting the 
overall analytic population to N =  1982 did not display 
different results, and VCAM had no significant statistical 
effect in any of the models, thus to improve precision of 
estimates our analytic sample was N = 2339.
For each biomarker subjects were classified into quar-
tiles based on their levels and participant characteristics 
were calculated by these quartiles. Proportional hazards 
(Cox) regression (SAS Proc PHREG) was used to exam-
ine the association between the quartiles of each of the 
biomarkers and incident T2D. We estimated the hazard 
ratio (HR) and corresponding 95  % confidence inter-
val (CI). Time to event was calculated from the baseline 
examination (year 15) as 5 or 10 years, namely the timing 
of the first follow-up examination meeting the criteria 
for the incident outcome (cases) or censoring at the last 
CARDIA exam without the incident outcome (censored).
A sequential modeling approach was applied. At later 
steps of the modeling, covariates were included that may 
or may not be on hypothetical causal pathways or may be 
co-determinants of risk. The main model included age 
(years), study center, race, sex, education (years), cigarette 
smoking (current, former, never), physical activity (units/
week), alcohol consumption (ml/day), family history 
of diabetes and sum of serum α-carotene, β-carotene, 
β-cryptoxanthin, and lutein/zeaxanthin (Sum4Carot), 
and serum α and γ tocopherols. We have reported that 
Sum4Carot is related to oxidative stress, endothelial dys-
function and inflammatory biomarkers [27], BMI [28], 
hypertension [29], and diabetes and smoking [24]. Serum 
carotenoids largely reflect dietary intake of fruit and veg-
etables [30].
Model 2 included model 1 plus the measures of oxi-
dative stress, inflammation and endothelial dysfunc-
tion not included in model 1. Model 3 added BMI to 
model 2. The last model included a metabolic syndrome 
(MetS) cluster score, consisting of the average of stand-
ardized deviates of the primary components of the MetS 
(i.e., the average of the z scores of waist circumference, 
systolic blood pressure, triglycerides, inverse HDL-
cholesterol, and fasting glucose) [31]. The score at 
any age can be computed as: 1/5*[(waist circumfer-
ence − 77.7)/11.4 − (HDL-cholesterol − 44.6)/10.2 + (tri-
glycerides  −  90.5)/52.9  +  (SBP  −  107.6)/9.2  +  (glu-
cose − 88.2)/7.4) [31]. A higher z-score indicates that the 
components tend to cluster in the higher sections of the 
distributions, i.e., represent overall higher risk. High scores 
are almost always the result of high values in two or more 
components. Consideration of coronary artery calcified 
plaque (CAC) as a measure of subclinical cardiovascular 
disease was considered in a sensitivity analysis. Details on 
the assessment of CAC are reported elsewhere [25]. Pres-
ence of CAC was defined as a non-zero Agatston score.
Additionally, we created an endothelial dysfunction 
index to test for any additive association of the different 
endothelial dysfunction biomarkers as well as test for an 
extended dose–response relationship. The hypothesis 
for this approach was informed by research showing the 
CAMs work in a “cascade” fashion in atherosclerosis [32], 
and thus higher levels of multiple CAMs reflect greater 
endothelial activation/inflammation (dysfunction) than 
an individual CAM. In an intermediary approach we 
summed the quartile ranks of the positively associated 
endothelial dysfunction biomarkers in this analysis with 
a similar modeling approach. There was no evidence that 
proportional hazards assumptions were violated for any 
of the exposures as indicated by the lack of significant 
interaction between them and time in the models. Tests 
for trend were performed entering the continuous vari-
able of each biomarker into the models. Effect modifica-
tion of the associations was considered by BMI, race, and 
sex.
Lastly, we examined whether these different biomark-
ers improved the prediction of diabetes relative to a com-
mon risk score utilized in research and clinical settings 
[33]. Due to concerns with net reclassification index 
(NRI) [34–37], we devised an alternative method. Spe-
cifically, to assess the improvement in prediction prob-
ability of an alternative risk score (formed by adding 
variables to a base risk score), we examined the gradient 
of observed diabetes risk across the reclassification of the 
predicted probability of the common base risk score. We 
formed a base risk score as the estimated mean, μB, of a 
Poisson distribution for predicting incident diabetes that 
included age, sex, race, family history, body-mass index, 
fasting glucose level, systolic blood pressure, high-density 
lipoprotein cholesterol level, and triglyceride level. Each 
person’s predicted base risk was saved and converted to 
a base probability using the formula  1 −  e−μB. We then 
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formed alternative risk scores by adding variables to the 
base risk score that were positively associated with inci-
dent T2D independent of the base risk score covariates 
in our Cox regression models, updating μB to μA, and 
forming the alternative probability 1  −  e−μA. For each 
participant, we subtracted alternative probability—base 
probability to get the reclassification probability (alterna-
tive probability ≥base probability corresponds to reclas-
sification up, alternative probability  <base probability 
corresponds to reclassification down).
The measure of improvement in prediction probabil-
ity has two parts: a graphic and a regression coefficient. 
The graphic displays the observed incident diabetes risk 
across reclassification probability (downward reclassi-
fication and upward reclassification) within quartiles of 
the base probability. An upward trend within a base risk 
category from downward reclassification probability—
upward reclassification probability indicates improved 
prediction probability. The regression coefficient arises 
in a further Poisson regression of incident diabetes 
(dependent variable) on reclassification probability, 
adjusting for base probability. The regression coefficient 
provides the estimated risk difference between the aver-
age person who is reclassified up (75th percentile of the 
reclassification probability) vs the average person who is 
reclassified down (25th percentile of the reclassification 
probability distribution) and is expressed as relative risk. 
A statistically significant regression coefficient indicates 
the existence of improved prediction probability and 
the magnitude of the relative risk indicates the extent of 
improvement in prediction probability. All analyses were 
conducted with SAS statistical software version 9.2 (SAS 
Institute, Cary, NC).
Results
The study sample of 2339 participants was aged 
32–47 years old (40.1 ± 3.6), was 56 % white, and 58 % 
women. Incident diabetes occurred in 222 people (9.5 %). 
Table 1 displays descriptive measures at year 15 for each 
of the main variables of interest.
Table  2 displays the hazard ratios for incident T2D 
according to levels of oxidative stress and inflamma-
tion. Relative to the lowest levels (bottom quartile) of 
F2-isoprostanes a monotonic positive association for 
risk of T2D in quartiles 2–4 was observed after adjust-
ment for demographic, lifestyle, serum carotenoids and 
tocopherols, and the other markers of oxidative stress, 
inflammation, and endothelial dysfunction. Upon adjust-
ment for BMI the association was attenuated. The other 
marker of oxidative stress in the cohort, oxidized LDL, 
displayed a threshold association where relative to quar-
tile 1, quartile 3 and 4 displayed a similar magnitude of 
positive association with incident T2D after adjustment 
for demographic, lifestyle, and other components of the 
etiological network. The association was largely attenu-
ated upon adjustment for BMI and the continuous meta-
bolic syndrome cluster score, although it persisted for Q3 
v. Q1. There was a strong positive association between 
higher levels of inflammation (CRP) and incident T2D. 
The nature of the association was graded in quartiles 2–4 
after adjustment for demographics, lifestyle factors and 
serum carotenoids and tocopherols; although the associ-
ations in Q2 and Q3 were positive but varying in strength 
and the estimates of HR became non-significant with 
adjustment for the other components of the etiological 
network. The magnitude of the association was strong for 
Q4 v. Q1 even after full adjustment for BMI and the MetS 
cluster score.
Table 3 displays the hazard ratios for T2D according to 
levels of cellular adhesion molecules (CAMS), markers 
of endothelial dysfunction. There was a strong, graded 
positive association in Q2-Q4 of ICAM-1 relative to Q1 
for incident T2D after adjustment for demographic, life-
style, etiologic network covariates, and BMI. However, 
adjustment for the MetS cluster score attenuated the 
significance of the association. The strong, graded posi-
tive association between levels of E-selectin and T2D was 
significant even after full adjustment. On the other hand 
there was no association between P-selectin and VCAM 
with incident T2DM.
To test the hypothesis that higher levels of multiple 
CAMs reflect greater endothelial dysfunction and por-
tend higher risk for T2D than an individual CAM we 
created an endothelial dysfunction index adding the 
quartiles of E-selectin and ICAM-1 with a possible rank 
sum of 2–8, the sum of two representing being in both 
the lowest quartile of each CAM and eight representing 
being in the highest quartile of each. The results of this 
analysis are presented in Table 4. Relative to a rank sum 
of 2–3, there was no association in scores of 4–5, but a 
strong, graded positive association for an index score 
range of 6–8. Including all four CAMs in the index did 
not change the magnitude of the estimates, but provided 
less precision (data not presented).
Figure  1 presents the results of the Improvement in 
Prediction Probability analysis. The graphic displays 
the results for the addition of E-selectin and ICAM-1 
as continuous variables to the base risk score. Within 
the graphic the observed diabetes incidence was plot-
ted as a reference across quartiles of the base risk score 
along with downward and upward reclassification 
probability according to the alternative risk score. The 
upward trends across categories indicate an improve-
ment in prediction probability over the base probability 
for that base risk quartile. The formal statistical tests 
and regression coefficient confirm this as the Relative 
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Table 1 Participant characteristics according to  levels of  oxidative stress, inflammation, and  endothelial dysfunction: 
CARDIA Year 15 (2000–2001)
Q1 Q2 Q3 Q4
Oxidative stress
 F2-Isoprostanes
  N 591 576 579 593
  F2-Isoprostanes (ng/mL) 31.9 (5.0) 44.5 (3.4) 58.2 (34.4) 100.2 (36.3)
  Age (years) 40.3 (3.6) 39.9 (3.5) 40.3 (3.7) 40.0 (3.8)
  Race (% black) 41.0 46.0 42.0 47.0
  Sex (% female) 46.0 49.0 57.0 82.0
  Education (years) 15.4 (2.5) 15.0 (2.5) 15.2 (2.5) 14.9 (2.3)
  BMI (kg/m2) 26.2 (4.6) 26.9 (4.9) 28.2 (6.1) 31.7 (7.6)
  Smoking (% current) 13.4 19.1 20.4 22.4
  Alcohol (% light-moderate) 45.8 47.4 41.1 30.8
  Alcohol (% heavy) 7.8 10.9 14.2 14.3
  Physical activityc 393.2 (281.4) 384.7 (286.2) 336.2 (266.3) 276.1 (239.9)
  Carotenoid index 81.9 (46.4) 70.6 (36.5) 61.4 (28.8) 51.2 (26.7)
Oxidized LDL
 N 580 588 598 573
 Oxidized LDL (U/L) 48.4 (9.3) 69.7 (4.8) 86.2 (5.5) 113.9 (14.7)
 Age (years) 40.1 (3.7) 40.2 (3.6) 40.0 (3.5) 40.1 (3.8)
 Race (% black) 38.0 45.0 45.0 48.0
 Sex (% female) 69.0 63.0 53.0 47.0
 Education (years) 15.4 (2.5) 15.2 (2.5) 15.1 (2.5) 14.8 (2.4)
 BMI (kg/m2) 26.0 (5.7) 28.1 (6.6) 28.6 (5.9) 30.3 (6.2)
 Smoking (% current) 17.5 18.3 20.0 19.3
 Alcohol (% light-moderate) 39.1 40.9 43.6 41.4
 Alcohol (% heavy) 14.5 11.6 10.8 10.2
 Physical activity 366.8 (270.5) 348.9 (281.2) 346.3 (274.4) 328.6 (264.0)
 Carotenoid index 67.9 (40.2) 67.8 (38.8) 65.4 (35.0) 64.0 (34.6)
Inflammation
 C-reactive protein
  N 582 602 587 568
  C-reactive protein (mg/L) 0.31 (0.12) 0.84 (0.22) 2.23 (0.63) 8.82 (7.24)
  Age (years) 39.9 (3.4) 40.2 (3.6) 40.4 (3.7) 39.9 (3.82)
  Race (% black) 34.0 37.0 46.0 59.0
  Sex (% female) 53.0 50.0 57.0 74.0
  Education (years) 15.4 (2.5) 15.3 (2.4) 15.0 (2.6) 14.7 (2.4)
  BMI (kg/m2) 24.5 (3.7) 26.8 (4.5) 28.8 (5.5) 33.0 (7.5)
  Smoking (% current) 13.7 19.4 18.8 23.3
  Alcohol (% light-moderate)a 45.6 43.1 40.4 35.9
  Alcohol (% heavy)b 12.1 12.7 12.7 9.5
  Physical activity 388.9 (277.8) 372.9 (273.6) 348.1 (274.0) 278.9 (252.9)
  Carotenoid index 81.3 (45.5) 69.2 (36.1) 61.9 (32.0) 52.3 (26.4)
Endothelial dysfunction
 ICAM-1
  N 597 589 571 582
  ICAM-1 (ng/mL) 111.3 (10.8) 134.9 (5.6) 157.0 (7.2) 204.3 (33.2)
  Age (years) 40.2 (3.5) 40.2 (3.6) 40.0 (3.6) 40.1 (3.8)
  Race (% black) 29.0 36.0 50.0 62.0
  Sex (% female) 64.0 57.0 56.0 55.0
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a  Alcohol: light-moderate (>0 to ≤7 drinks/week female, >0 to ≤14 drinks/week male)
b  Alcohol: heavy (>7 drinks/week female, >14 drinks/week male)
c  Physical activity: exercise units
Table 1 continued
Q1 Q2 Q3 Q4
  Education (years) 15.8 (2.3) 15.5 (2.5) 15.0 (2.5) 14.2 (2.2)
  BMI (kg/m2) 25.7 (4.7) 27.3 (5.7) 29.2 (6.0) 30.9 (7.3)
  Smoking (% current) 7.9 11.5 18.4 38.3
  Alcohol (% light-moderate) 48.5 42.9 36.7 36.7
  Alcohol (% heavy) 12.5 9.7 11.6 13.3
  Physical activity 388.0 (284.7) 368.0 (270.7) 341.5 (277.4) 290.2 (247.5)
  Carotenoid index 80.0 (38.6) 70.5 (36.6) 63.2 (38.3) 50.6 (27.0)
 E-selectin
  N 591 580 583 585
  E-selectin (ng/mL) 18.4 (4.3) 29.0 (2.5) 38.0 (2.7) 51.7 (7.4)
  Age (years) 40.3 (3.6) 40.1 (3.5) 40.1 (3.7) 39.9 (3.8)
  Race (% black) 31.0 38.0 49.0 59.0
  Sex (% female) 71.0 63.0 53.0 45.0
  Education (years) 15.7 (2.4) 15.2 (2.5) 15.1 (2.5) 14.5 (2.3)
  BMI (kg/m2) 26.1 (5.6) 27.2 (5.4) 29.2 (6.3) 30.6 (6.9)
  Smoking (% current) 11.0 17.1 20.5 27.2
  Alcohol (% light-moderate) 42.7 42.0 41.8 38.5
  Alcohol (% heavy) 11.4 10.4 10.6 14.8
  Physical activity 357.1 (274.2) 351.7 (272.0) 348.5 (285.6) 332.6 (258.7)
  Carotenoid index 78.1 (40.5) 69.7 (40.1) 60.5 (31.3) 56.0 (31.8)
 P-selectin
  N 575 590 592 574
  P-selectin (ng/mL) 24.5 (4.0) 32.4 (1.7) 38.8 (2.0) 50.8 (10.7)
  Age (years) 40.3 (3.6) 39.9 (3.6) 40.1 (3.8) 40.2 (3.6)
  Race (% black) 41.0 44.0 48.0 43.0
  Sex (% female) 73.0 65.0 54.0 40.0
  Education (years) 15.6 (2.5) 15.0 (2.4) 14.9 (2.4) 14.0 (2.5)
  BMI (kg/m2) 26.9 (5.7) 27.9 (6.2) 29.2 (6.5) 29.0 (6.5)
  Smoking (% current) 11.8 17.3 18.3 28.5
  Alcohol (% light-moderate) 40.8 41.8 39.6 43.0
  Alcohol (% heavy) 11.6 10.3 12.0 13.4
  Physical activity 354.3 (279.1) 333.6 (262.6) 356.7 (277.5) 346.6 (272.6)
73.0 (38.6) 66.7 (40.5) 62.9 (33.2) 62.1 (34.9)
 VCAM
  N 489 497 502 494
  VCAM (ng/mL) 352.0 (48.1) 457.0 (25.7) 554.3 (30.4) 741.1 (148.1)
  Age (years) 39.8 (3.7) 40.0 (3.7) 40.0 (3.6) 40.7 (3.5)
  Race (% black) 67.0 49.0 39.0 22.0
  Sex (% female) 61.0 59.0 57.0 56.0
  Education (years) 14.7 (2.4) 15.2 (2.5) 15.2 (2.5) 15.5 (2.5)
  BMI (kg/m2) 29.7 (6.1) 28.9 (6.5) 28.2 (6.5) 26.2 (5.5)
  Smoking (% current) 24.6 20.3 16.6 13.6
  Alcohol (% light-moderate) 39.0 40.2 39.2 46.8
  Alcohol (% heavy) 13.6 11.9 11.9 9.8
  Physical activity 323.2 (257.7) 345.7 (286.8) 350.3 (269.3) 371.2 (275.3)
  Carotenoid index 63.1 (33.5) 64.4 (32.5) 67.5 (40.2) 70.2 (41.6)
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Risk (RR) for the 75 vs 25th  % of the alternative risk 
score Probability was RR  =  1.09, 95  % Confidence 
interval (1.06–1.13), P < 0.0001. Therefore, there was a 
relative 9 % improvement in prediction probability with 
the alternative risk score adding markers of endothelial 
dysfunction to the base risk score. Alternatively, CRP 
did not improve prediction probability of diabetes (data 
not reported).
We carried out a number of sensitivity analyses. There 
was no evidence that the associations differed for any 
of the measures by race, sex or BMI. In analyses that 
accounted for the overall individual factors comprising 
metabolic syndrome, rather than a continuous score, as 
well as LDL cholesterol, we observed no material dif-
ferences in the findings except this approach led to less 
precise estimates and model fits. Further adjustment for 
year 15 blood pressure medication also did not affect the 
results. In another approach we further adjusted for year 
15 adiponectin, a potential mediator of these markers and 
T2D, and this did not impact any of the findings. Since 
dysglycemia contributes to an environment of oxida-
tive stress, inflammation and endothelial dysfunction we 
excluded all participants with impaired fasting glucose 
(IFG) (N = 357) at year 15 and this also didn’t alter the 
nature of any of the results, neither did excluding glucose 
from the continuous metabolic risk score. Furthermore, 
we examined whether the results were dependent on the 
presence of subclinical cardiovascular disease (CAC) at 
year 15; neither adjustment for year 15 CAC nor exclu-
sion of 182 participants with any CAC had any material 
effect on the results.
Discussion
This population based study, comprised of young to 
early middle aged black and white adults, showed that 
biomarkers of an etiological network of oxidative stress, 
inflammatory, and endothelial dysfunction biomarkers 
predicted T2D. Biomarkers of oxidative stress, F2-iso-
prostanes and oxidized LDL, were positively associ-
ated with incident T2D, however, adjustment for BMI 
Table 2 Hazard ratio and  95  % confidence interval of  type 2 diabetes according to  measures of  oxidative stress 
and inflammation: CARDIA year 15–25 (2000–2001 to 2010–11)
Oxidative stress
Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, physical activity, family history, serum carotenoids and tocopherols, Model 2 Model 
1 + alternative oxidative stress marker, inflammation (C-reactive protein), endothelial dysfunction (CAMs), Model 3 Model 2 + BMI, Model 4 Model 3 + Continuous 
Metabolic Syndrome Score
Inflammation
Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, physical activity, family history, serum carotenoids and tocopherols, Model 2 Model 
1 + oxidative stress (oxldl, isoprostanes), endothelial dysfunction (CAMS), Model 3 Model 2 + BMI, Model 4 Model 3 + continuous metabolic syndrome score, P Trend P 
value for continuous variable
Oxidative stress
Q1 Q2 Q3 Q4 P trend
F2-isoprostanes
 N cases/N 36/591 45/576 56/579 85/593
 Model 1 1.00 1.12 (0.72–1.75) 1.25 (0.81–1.93) 1.83 (1.18–2.83) 0.005
 Model 2 1.00 1.09 (0.70–1.70) 1.28 (0.83–1.98) 1.61 (1.03–2.52) 0.11
 Model 3 1.00 1.10 (0.71–1.72) 1.14 (0.73–1.76) 1.22 (0.77–1.93) 0.86
 Model 4 1.00 1.19 (0.76–1.86) 1.17 (0.75–1.81) 1.43 (0.90–2.26) 0.71
Oxidized LDL
 N cases/N 31/580 43/588 70/598 78/573
 Model 1 1.00 1.25 (0.79–1.99) 2.06 (1.34–3.17) 1.97 (1.27–3.05) 0.0006
 Model 2 1.00 1.29 (0.81–2.05) 2.16 (1.41–3.31) 2.09 (1.37–3.18) <0.0001
 Model 3 1.00 1.03 (0.65–1.65) 1.76 (1.14–2.71) 1.46 (0.94–2.28) 0.03
 Model 4 1.00 1.06 (0.66–1.70) 1.62 (1.05–2.51) 1.31 (0.83–2.04) 0.14
Inflammation
 C-reactive protein
  N cases/N 18/582 44/602 51/587 109/568
  Model 1 1.00 1.88 (1.08–3.28) 1.97 (1.14–3.39) 3.98 (2.36–6.71) <0.0001
  Model 2 1.00 1.83 (1.05–3.18) 1.67 (0.96–2.90) 2.95 (1.73–5.04) <0.0001
  Model 3 1.00 1.63 (0.93–2.84) 1.42 (0.82–2.48) 2.06 (1.17–3.61) 0.09
  Model 4 1.00 1.64 (0.94–2.87) 1.41 (0.81–2.46) 2.21 (1.26–3.88) 0.022
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attenuated the association. We corroborated that inflam-
mation (C-reactive protein) was positively associated 
with T2D even with full adjustment for related path-
ways. Lastly, we observed that higher levels of a plasma 
biomarker of endothelial dysfunction (E-selectin) were 
strongly associated with T2D even after full adjustment, 
although another CAM (ICAM-1) was attenuated upon 
adjustment for metabolic risk factors. An index of these 
two CAMs revealed an extended dose–response with a 
greater magnitude of association; whereas the other two 
CAMs measured (P-selectin and VCAM) were not asso-
ciated with T2D. Overall, the addition of E-selectin and 
ICAM-1 improved the prediction of T2D over a com-
mon base risk model. There was no evidence any of these 
Table 3 Hazard ratio and 95 % confidence interval of type 2 diabetes according to measures of endothelial dysfunction: 
CARDIA year 15–25 (2000–2001 to 2010–11)
Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, physical activity, family history, carotenoids and tocopherols, Model 2 Model 1 + other 
endothelial dysfunction markers (CAMs), oxidative stress (oxldl, isoprostanes), inflammation (CRP), Model 3 Model 2 + BMI, Model 4 Model 3 + continuous metabolic 
syndrome score
Q1 Q2 Q3 Q4 P trend
ICAM-1
 N cases/N 21/597 41/589 59/571 101/582
 Model 1 1.00 1.73 (1.02–2.93) 2.28 (1.37–3.78) 3.20 (1.94–5.27) <0.0001
 Model 2 1.00 1.47 (0.87–2.51) 1.73 (1.03–2.91) 1.94 (1.14–3.31) 0.11
 Model 3 1.00 1.37 (0.81–2.34) 1.56 (0.92–2.62) 1.72 (1.01–2.94) 0.07
 Model 4 1.00 1.31 (0.77–2.25) 1.50 (0.89–2.52) 1.64 (0.96–2.81) 0.20
E-selectin
 N cases/N 28/591 32/580 61/583 101/585
 Model 1 1.00 0.99 (0.59–1.65) 1.69 (1.07–2.66) 2.48 (1.60–3.85) <0.0001
 Model 2 1.00 1.00 (0.59–1.68) 1.56 (0.97–2.49) 2.10 (1.31–3.38) <0.0001
 Model 3 1.00 1.01 (0.60–1.69) 1.34 (0.84–2.15) 1.76 (1.09–2.83) 0.0008
 Model 4 1.00 0.99 (0.59–1.67) 1.30 (0.81–2.09) 1.68 (1.04–2.71) 0.0016
P-selectin
 N cases/N 41/575 42/590 67/592 70/574
 Model 1 1.00 0.92 (0.59–1.41) 1.38 (0.93–2.06) 1.48 (0.98–2.22) 0.097
 Model 2 1.00 0.76 (0.68–1.54) 1.02 (0.68–1.54) 0.93 (0.60–1.43) 0.58
 Model 3 1.00 0.78 (0.50–1.22) 0.96 (0.64–1.45) 0.89 (0.58–1.37) 0.49
 Model 4 1.00 0.78 (0.50–1.21) 0.93 (0.62–1.41) 0.80 (0.52–1.24) 0.32
VCAM
 N cases/N 58/489 56/497 42/502 30/494
 Model 1 1.00 1.14 (0.79–1.66) 0.86 (0.57–1.29) 0.75 (0.47–1.19) 0.30
 Model 2 1.00 1.16 (0.80–1.69) 0.87 (0.58–1.32) 0.71 (0.43–1.15 0.09
 Model 3 1.00 1.09 (0.75–1.59) 0.89 (0.59–1.34) 0.78 (0.48–1.29) 0.28
 Model 4 1.00 1.04 (0.71–1.52) 0.85 (0.56–1.28) 0.83 (0.51–1.38) 0.31
Table 4 Hazard ratio and  95  % confidence interval of  type 2 diabetes according to  endothelial dysfunction index 
(E-selectin + ICAM-1) CARDIA year 15–25 (2000–2001 to 2010–11)
Rank sum combined rank sum of quartiles of E-selectin and ICAM-1(1–4 each, 8 total possible), Model 1 adjusted for age, sex, race, center, education, smoking, alcohol, 
physical activity, family history, carotenoids and tocopherols, Model 2 Model 1 + oxidative stress (oxidized LDL, isoprostanes) and inflammation (CRP), Model 3 Model 
2 + BMI, Model 4 Model 3 + continuous metabolic syndrome score
Rank sum 2–3 4 5 6 7 8 P trend
N cases/N 22/568 22/396 24/379 43/387 51/320 60/267
Model 1 1.00 1.31 (0.72–2.37) 1.37 (0.76–2.46) 2.23 (1.32–3.78) 2.90 (1.72–4.89) 3.76 (2.23–6.34) <0.0001
Model 2 1.00 1.23 (0.68–2.23) 1.25 (0.70–2.26) 2.03 (1.19–3.44) 2.53 (1.49–4.28) 3.07 (1.79–5.25) <0.0001
Model 3 1.00 1.13 (0.63–2.06) 1.09 (0.60–1.98) 1.81 (1.06–3.09) 2.00 (1.16–3.45) 2.49 (1.43–4.33) <0.0001
Model 4 1.00 1.22 (0.67–2.23) 1.04 (0.57–1.90) 1.91 (1.11–3.27) 1.92 (1.11–3.30) 2.34 (1.34–4.09) 0.0002
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results were modified by race, sex, BMI, IFG, adiponec-
tin, or sub-clinical CVD (CAC).
The results from this study related to oxidative stress 
contribute novel data to the literature as there has been 
little prospective study of the association between plasma 
markers of oxidative stress and T2D. In a case-cohort 
analysis from the ARIC study higher levels of oxidized 
LDL were positively associated with T2D in a simple 
model, and in the context of high levels of ICAM-1, but 
with further adjustment for established risk factors there 
was no association [18]. Similar results were observed in 
the Framingham Heart Study for urinary isoprostanes 
[38]. On the other hand higher urinary isoprostane lev-
els in the IRAS study were inversely associated with T2D 
[9]. Indeed, urine and plasma measures of isoprostanes 
are not necessarily equivalent measures [39]. Further-
more, oxidized LDL and isoprostanes represent different 
aspects of oxidative stress where the former likely repre-
sents a local measure in the vasculature and the latter a 
more general marker of a specific oxidation pathway [40]. 
These differences may explain the subtleties in the asso-
ciation with T2D in this study.
The results from this analysis related to CRP are con-
firmatory [11], but the context and population we exam-
ined the question in is unique with factors that are likely 
upstream, downstream and co-determinants. Unlike 
measures of inflammation only a few studies have exam-
ined vascular biomarkers of endothelial dysfunction and 
risk of T2D. The Nurses’ Health Study observed a strong 
positive association between higher levels of E-selectin 
and ICAM-1 with T2D and a non-significant association 
with VCAM [14]. The WHI had similar findings [16]. The 
MONICA study observed a similar trend with E-selectin 
but the ICAM-1 association was only apparent in simple 
models [15]. The ARIC study only observed a positive 
association between high levels of ICAM-1 and T2D with 
high levels of oxidized LDL providing evidence for the 
hypothesis that endothelial dysfunction needs the pres-
ence of oxidative stress to alter T2D risk. We observed 
a higher incidence rate of T2D with higher levels of 
X axis: Quartiles of Diabetes Risk Score (Includes age, sex, race, family history, body-mass index, fasting glucose level, systolic blood pressure,
high-density lipoprotein cholesterol level, and triglyceride level ).  
Y axis: Actual incidence (%, probability) of T2D and estimated incidence (%, probability) of T2D upon reclassification 
BP: Base Probability 
AP: Alternative Probability 













Improvement in Predicon Probability of Type 2 Diabetes:
Addion of E-Selecn and ICAM-1 to Base Risk Model
RP: Down BP RP: Up
381 584   203 352 585 233  342  585  243       343         585        232
Fig. 1 Results from the Improvement in Prediction Probability analysis adding E-selectin and ICAM-1 to a base risk score for T2D: The base risk 
score was ranked into quartiles (Q1–Q4). For each BP quartile, observed T2D incidence was plotted (middle bar in bold) as a reference point without 
reclassification. For each participant k, reclassification probability < 0 is labeled “Down”. Reclassification probability ≥0 is labeled “Up”. Participants 
reclassified “down” and “up” are plotted to the left and right of overall base risk within each BP quartile. The numbers on the X axis of the graph repre-
sent the N reclassified down or up and the overall N of the quartile (N “down” + N “up” = N “base”). The numbers (in italics) above each bar represent 
the estimated probability of incident T2D in participants reclassified down and up. When the probability of incident T2D for reclassification “up” is 
greater than the probability of incident T2D for reclassification “down”, there is improvement in prediction probability. A formal statistical test used 
Poisson regression of incident T2D dependent variable) on AP–BP, adjusting for BP. The Relative Risk for the midpoint of those reclassified “up” (75th 
percentile of AP–BP) vs the midpoint of reclassification “down” (75th percentile of AP–BP) was 1.09, 95 % Confidence interval (1.06–1.13), P < 0.0001
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ICAM-1 regardless of oxidized LDL level, although the 
highest rates were in those with the highest levels of oxi-
dized LDL (data not presented).
The results from this analysis are largely consist-
ent with the results from the Nurses’ Health Study and 
the WHI even with the different design and modeling 
approach. The population in this analysis was a sample 
from a community based study, was significantly younger 
and diverse by race, sex, and socioeconomic position. 
The results related to the index of levels of E-selectin 
and ICAM-1 suggest that high levels of both portend a 
greater risk for T2D than individual consideration of 
each CAM. Aligned with these results related to vascular 
biomarkers of endothelial dysfunction and T2D risk are 
a handful of studies that observed a positive association 
between other measures of endothelial dysfunction and 
increased risk of T2D [41–44]. Lastly, despite the evi-
dence of an etiologic role of these markers of oxidative 
stress, inflammation and endothelial dysfunction in the 
development of T2D the addition of them to established 
clinical risk prediction equations did not improve predic-
tion [38, 45, 46]. Highlighting the differences between 
etiology and prediction. Yet, the endothelial dysfunction 
biomarkers improved prediction in the current study.
These population studies are evidence in support of 
vascular dysfunction in the etiology of T2D. But to give 
this research context it is important to also consider evi-
dence and mechanisms at the cellular level. This literature 
suggests these factors under study are likely functioning 
in a cascade or network with pathophysiological conse-
quences [1], but evidence for each has a demonstrated 
role in the etiology of T2D. Specifically, generalized oxi-
dative stress damages mitochondria and dulls insulin 
secretion [5]. Oxidized LDL may have an etiologic role by 
reducing insulin signaling [47], and glucose uptake [48]. 
In an inflammatory state a cascade of reactions occur 
that harm vascular reactivity and insulin delivery and 
lead to insulin resistance [49]. Lastly, clinical and experi-
mental studies suggest that endothelial dysfunction, 
likely in the capillary and arteriolar endothelium, which 
are metabolically involved with insulin-sensitive tissues, 
is the controlling factor for the amount of insulin that 
effectively reaches the tissues [50]. Thus, there is a strong 
basic biological precedent for the population level results 
we and others have observed.
Strengths of this research include the novelty of pro-
spectively examining the association between serum 
and plasma biomarkers of oxidative stress and endothe-
lial dysfunction with T2D in the context of one another 
and inflammation. Furthermore, the ability to character-
ize the metabolic and cardiovascular risk status of the 
population, and to demonstrate that the observed results 
were not due to an underlying condition, strengthens 
the etiological insight this study provides. Addition-
ally, CARDIA has maintained a high participation rate 
and high quality data collection through rigorous qual-
ity-control procedures throughout the study. Thus, the 
results from this large community-based sample are gen-
eralizable to women, men, blacks and whites. Further, 
the ability to examine this topic in a younger population 
(age 33–45 years) is a unique contribution to the litera-
ture. Limitations include interpretation of the oxidative 
stress results—the measures of oxidative stress were not 
correlated with each other, which reflects the complexity 
of oxidative stress, and emphasizes caution in extrapolat-
ing these results to other measures related to oxidative 
stress. CRP is a non-specific marker of inflammation and 
other measures such as IL-6, which drive the production 
of CRP in the liver may be more specific relative to this 
topic [49]. Endothelial dysfunction was assessed solely 
by serum/plasma biomarkers and we did not have other 
measures of vascular physiology. Regardless of measure-
ment, consideration of residual confounding is important 
in any observational study.
Conclusions
These findings extend the literature from earlier studies 
on circulating measures of endothelial dysfunction and 
risk of T2D, and contribute novel data related to oxida-
tive stress and risk of T2D by assessing these factors in 
the context of one another and other relevant pathways 
including a marker of inflammation, metabolic syndrome 
components and BMI. Overall, these results demonstrate 
that higher circulating levels of oxidative stress, inflam-
matory and endothelial dysfunction biomarkers clearly 
precede the development of T2D.
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